Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis

被引:54
作者
Murphy, Sarah E. [1 ]
Bicanic, Tihana [1 ,2 ]
机构
[1] St Georges Univ London, Inst Infect & Immun, London, England
[2] St Georges Univ Hosp Natl Hlth Serv NHS Fdn Trust, Clin Acad Grp Infect & Immun, London, England
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2021年 / 11卷
关键词
Candida; invasive candidiasis; candidaemia; antifungal resistance; antifungal drugs; drug therapy; drug resistance; antimicrobial resistance; BROAD-SPECTRUM ANTIFUNGAL; GLUCAN SYNTHASE INHIBITOR; LONG-ACTING ECHINOCANDIN; IN-VITRO ACTIVITY; INFECTIOUS-DISEASES SOCIETY; CELECOXIB DERIVATIVE AR-12; HIGHLY POTENT INHIBITOR; AMPHOTERICIN-B; MURINE MODEL; TREHALOSE-6-PHOSPHATE PHOSPHATASE;
D O I
10.3389/fcimb.2021.759408
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Candida species are the leading cause of invasive fungal infections worldwide and are associated with acute mortality rates of ~50%. Mortality rates are further augmented in the context of host immunosuppression and infection with drug-resistant Candida species. In this review, we outline antifungal drugs already in clinical use for invasive candidiasis and candidaemia, their targets and mechanisms of resistance in clinically relevant Candida species, encompassing not only classical resistance, but also heteroresistance and tolerance. We describe novel antifungal agents and targets in pre-clinical and clinical development, including their spectrum of activity, antifungal target, clinical trial data and potential in treatment of drug-resistant Candida. Lastly, we discuss the use of combination therapy between conventional and repurposed agents as a potential strategy to combat the threat of emerging resistance in Candida.
引用
收藏
页数:22
相关论文
共 234 条
  • [1] Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
    Aigner, Maria
    Lass-Floerl, Cornelia
    [J]. JOURNAL OF FUNGI, 2020, 6 (02)
  • [2] Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
    Arendrup, M. C.
    Meletiadis, J.
    Zaragoza, O.
    Jorgensen, K. M.
    Marcos-Zambrano, L. J.
    Kanioura, L.
    Cuenca-Estrella, M.
    Mouton, J. W.
    Guinea, J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (11) : 1200 - 1204
  • [3] Echinocandin resistance: an emerging clinical problem?
    Arendrup, Maiken C.
    Perlin, David S.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2014, 27 (06) : 484 - 492
  • [4] EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)
    Arendrup, Maiken C.
    Cuenca-Estrella, Manuel
    Lass-Floerl, Cornelia
    Hope, William
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) : E246 - E247
  • [5] Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs
    Arendrup, Maiken Cavling
    Jorgensen, Karin Meinike
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [6] Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis
    Arendrup, Maiken Cavling
    Andersen, Jakob S.
    Holten, Mads Kristian
    Krarup, Kenneth B.
    Reiter, Nanna
    Schierbeck, Jens
    Helleberg, Marie
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (05):
  • [7] Arendrup MC, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01225-18, 10.1128/aac.01225-18]
  • [8] Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
    Arendrup, Maiken Cavling
    Perlin, David S.
    Jensen, Rasmus Hare
    Howard, Susan Julie
    Goodwin, Joanne
    Hope, William
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2435 - 2442
  • [9] Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis
    Azie, Nkechi
    Angulo, David
    Dehn, Barbara
    Sobel, Jack D.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 893 - 900
  • [10] Calcineurin is essential for virulence in Candida albicans
    Bader, T
    Bodendorfer, B
    Schröppel, K
    Morschhäuser, J
    [J]. INFECTION AND IMMUNITY, 2003, 71 (09) : 5344 - 5354